Cell Therapy
Stem Cell Transplant for Sickle Cell Anemia
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial tests a new bone marrow transplant method for adults with sickle cell disease and Beta-thalassemia. It uses stem cells from a half-matched family donor, low-dose radiation, and immunosuppressant drugs, but no chemotherapy. The goal is to reduce complications and improve outcomes for patients who lack fully matched donors.
Cell Therapy
Bone Marrow Transplant for Sickle Cell Disease
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial uses stem cells from mismatched donors with certain immune cells removed to treat patients with severe blood disorders who lack a perfect donor match. The approach aims to replace damaged cells, reduce complications, and support recovery with additional immune cells. A new technique has been developed to improve the treatment process.
Alkylating agents
Stem Cell Transplant for Severe Aplastic Anemia
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is for people with severe aplastic anemia, myelodysplastic syndrome, or paroxysmal nocturnal hemoglobinuria who want to receive a stem cell transplant using peripheral blood stem cells from a family member.
Flavonoid
Quercetin for Squamous Cell Cancer in Fanconi Anemia
Recruiting1 awardPhase 2
Cincinnati, Ohio
This trial is testing whether the supplement quercetin can prevent or delay the development of skin cancer in people with Fanconi anemia, a rare disease that leads to bone marrow failure and a higher risk for certain cancers.
Popular Filters
Trials for Myelodysplastic Syndrome Patients
Anti-metabolites
Reduced-Intensity Stem Cell Transplant for Non-Malignant Disorders
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing whether a reduced-intensity conditioning regimen followed by umbilical cord blood transplant, double cord blood transplant, matched unrelated donor bone marrow transplant, or peripheral blood stem cell transplant is effective in treating patients with non-malignant disorders.
Protein Therapeutics
Luspatercept vs Epoetin Alfa for MDS-related Anemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial will compare luspatercept to epoetin alfa to see if luspatercept is more effective in increasing hemoglobin and reducing the need for RBC transfusions in patients with anemia due to MDS.
Trials for Iron-Deficiency Anemia Patients
Anti-metabolites
Reduced-Intensity Stem Cell Transplant for Non-Malignant Disorders
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing whether a reduced-intensity conditioning regimen followed by umbilical cord blood transplant, double cord blood transplant, matched unrelated donor bone marrow transplant, or peripheral blood stem cell transplant is effective in treating patients with non-malignant disorders.
Chemotherapy
INCB000928 + Ruxolitinib for Myelofibrosis
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is testing a new drug called INCB000928, either alone or with ruxolitinib, to see if it is safe and effective. It targets people with Myelofibrosis who need regular blood transfusions or have severe anemia. The goal is to see if the drug can reduce the need for transfusions and improve anemia symptoms.
Erythropoiesis-Stimulating Agent
Darbe + IV Iron for Premature Infants
Recruiting3 awardsPhase 2
Seattle, Washington
This trial uses Darbepoetin and slow-release IV iron to help preterm infants. The treatment aims to reduce the need for blood transfusions, keep iron levels stable, and support better brain development without causing stomach problems.
Phase 3 Trials
Protein Therapeutics
Luspatercept vs Epoetin Alfa for MDS-related Anemia
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial will compare luspatercept to epoetin alfa to see if luspatercept is more effective in increasing hemoglobin and reducing the need for RBC transfusions in patients with anemia due to MDS.
Monoclonal Antibodies
M281 for Autoimmune Hemolytic Anemia
Recruiting0 awardsPhase 2 & 3
Riverside, California
This trial is testing a medication called nipocalimab to see if it can help people with a blood disorder called warm autoimmune hemolytic anemia. The medication works by stopping the immune system from destroying red blood cells, which can help reduce anemia symptoms.
Trials With No Placebo
Anti-metabolites
Reduced-Intensity Stem Cell Transplant for Non-Malignant Disorders
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing whether a reduced-intensity conditioning regimen followed by umbilical cord blood transplant, double cord blood transplant, matched unrelated donor bone marrow transplant, or peripheral blood stem cell transplant is effective in treating patients with non-malignant disorders.
Thrombopoietin Receptor Agonist
Eltrombopag for Aplastic Anemia
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is evaluating the safety and effectiveness of eltrombopag, a drug given by mouth, in people with moderate aplastic anemia or bone marrow failure and unilineage cytopenia who need treatment for significantly low blood cell counts.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.